BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van der Have M, Oldenburg B, Kaptein AA, Jansen JM, Scheffer RC, van Tuyl BA, van der Meulen-de Jong AE, Pierik M, Siersema PD, van Oijen MG. Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study. J Crohns Colitis. 2016;10:549-555. [PMID: 26738757 DOI: 10.1093/ecco-jcc/jjw002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Wentworth BJ, Buerlein RCD, Tuskey AG, Overby MA, Smolkin ME, Behm BW. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:2053-61. [DOI: 10.1093/ibd/izy102] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
2 Khan N, Patel D, Xie D, Pernes T, Lewis J, Yang YX. Adherence of Infusible Biologics During the Time of COVID-19 Among Patients With Inflammatory Bowel Disease: A Nationwide Veterans Affairs Cohort Study. Gastroenterology 2020;159:1592-1594.e1. [PMID: 32574622 DOI: 10.1053/j.gastro.2020.06.044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
3 Nieto JC, Arajol C, Carmona L, Marras C, Cea-Calvo L. Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review. Immunotherapy 2021;13:433-58. [PMID: 33557600 DOI: 10.2217/imt-2021-0011] [Reference Citation Analysis]
4 Ramos L, Ramos-Rodríguez J, Barreda R, Gutiérrez-Nicolás F, Carrillo-Palau M, Alonso-Abreu I, Nazco-Casariego J, Quintero E. Adherence to subcutaneous biologic treatment for inflammatory bowel disease. Gastroenterol Hepatol 2021:S0210-5705(21)00169-2. [PMID: 34051312 DOI: 10.1016/j.gastrohep.2021.04.011] [Reference Citation Analysis]
5 Helwig U, Kostev K, Schmidt C. Comparative Analysis of 3-Year Persistence With Vedolizumab Compared With Antibodies Against Tumor Necrosis Factor-Alpha in Patients With Inflammatory Bowel Disease in Germany: Retrospective Analysis of a Large Prescription Database. J Clin Gastroenterol 2021;55:e1-7. [PMID: 32011403 DOI: 10.1097/MCG.0000000000001323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review. J Clin Pharm Ther 2019;44:495-507. [PMID: 30873648 DOI: 10.1111/jcpt.12830] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
7 Abegunde AT, Muhammad BH, Ali T. Preventive health measures in inflammatory bowel disease. World J Gastroenterol 2016; 22(34): 7625-7644 [PMID: 27678347 DOI: 10.3748/wjg.v22.i34.7625] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
8 Gely C, Marín L, Gordillo J, Mañosa M, Bertoletti F, Cañete F, González-Muñoza C, Calafat M, Domènech E, Garcia-Planella E. Impact of pain associated with the subcutaneous administration of adalimumab. Gastroenterol Hepatol 2020;43:9-13. [PMID: 31492425 DOI: 10.1016/j.gastrohep.2019.06.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
9 Shah NB, Haydek J, Slaughter J, Ashton JR, Zuckerman AD, Wong R, Raffa F, Garrett A, Duley C, Annis K, Wagnon J, Gaines L, Dalal R, Scoville E, Beaulieu DB, Schwartz D, Horst SN. Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:314-20. [PMID: 31671188 DOI: 10.1093/ibd/izz253] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
10 Lenti MV, Selinger CP. Patients' Beliefs and Concerns About the Necessity of Long-Term Therapies Are Crucial for Medication Adherence for Inflammatory Bowel Disease. J Crohns Colitis 2017;11:764-5. [PMID: 27932452 DOI: 10.1093/ecco-jcc/jjw213] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
11 Ottaviani S, Forien M. [Compliance with biologic agents: Current situation]. Rev Mal Respir 2021;38:698-705. [PMID: 34140211 DOI: 10.1016/j.rmr.2021.06.001] [Reference Citation Analysis]
12 Martelli L, Lopez A, Strobel S, Danese S, Roblin X, Baumann C, Peyrin-biroulet L. Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting: Adherence to infliximab in IBD. Journal of Digestive Diseases 2017;18:566-73. [DOI: 10.1111/1751-2980.12539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
13 Lenti MV, Selinger CP. Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions. Expert Rev Gastroenterol Hepatol 2017;11:215-26. [PMID: 28099821 DOI: 10.1080/17474124.2017.1284587] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
14 Schultheiss JPD, Altena S, Clevers MR, Baas D, Jharap B, Fidder HH. Adherence to Adalimumab Was Not Improved by a Reminder-Based Intervention with an Electronic Needle Container. Dig Dis Sci 2021;66:1477-87. [PMID: 32556818 DOI: 10.1007/s10620-020-06395-z] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Chan W, Chen A, Tiao D, Selinger C, Leong R. Medication adherence in inflammatory bowel disease. Intest Res 2017;15:434-45. [PMID: 29142511 DOI: 10.5217/ir.2017.15.4.434] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 11.8] [Reference Citation Analysis]
16 Artom M, Czuber-Dochan W, Sturt J, Murrells T, Norton C. The contribution of clinical and psychosocial factors to fatigue in 182 patients with inflammatory bowel disease: a cross-sectional study. Aliment Pharmacol Ther. 2017;45:403-416. [PMID: 27868215 DOI: 10.1111/apt.13870] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
17 Stone ML, Feng M, Forster EM. COVID-19 Pandemic Increased Anxiety Among Patients with Inflammatory Bowel Disease: A Patient Survey in a Tertiary Referral Center. Dig Dis Sci 2021. [PMID: 34115232 DOI: 10.1007/s10620-021-07095-y] [Reference Citation Analysis]
18 Perry J, Chen A, Kariyawasam V, Collins G, Choong C, Teh WL, Mitrev N, Kohler F, Leong RWL. Medication non-adherence in inflammatory bowel diseases is associated with disability. Intest Res 2018;16:571-8. [PMID: 30301333 DOI: 10.5217/ir.2018.00033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
19 Bruna-Barranco I, Lué A, Gargallo-Puyuelo CJ, Arroyo MT, Alfambra E, Montero J, Gomollón F. Young age and tobacco use are predictors of lower medication adherence in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2019;31:948-53. [PMID: 31107739 DOI: 10.1097/MEG.0000000000001436] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
20 Min Ho PY, Hu W, Lee YY, Gao C, Tan YZ, Cheen HH, Wee HL, Lim TG, Ong WC. Health-related quality of life of patients with inflammatory bowel disease in Singapore. Intest Res 2019;17:107-18. [PMID: 30419638 DOI: 10.5217/ir.2018.00099] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
21 Ben Ghezala I, Charkaoui M, Michiels C, Bardou M, Luu M. Small Molecule Drugs in Inflammatory Bowel Diseases. Pharmaceuticals (Basel) 2021;14:637. [PMID: 34209234 DOI: 10.3390/ph14070637] [Reference Citation Analysis]
22 Dart RJ, Samaan MA, Powell N, Irving PM. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. Clin Exp Gastroenterol 2017;10:57-66. [PMID: 28424557 DOI: 10.2147/CEG.S110547] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
23 Eindor-Abarbanel A, Naftali T, Ruhimovich N, Bar-Gil Shitrit A, Sklerovsky-Benjaminov F, Konikoff F, Matalon S, Shirin H, Milgrom Y, Broide E. Revealing the Puzzle of Nonadherence in IBD-Assembling the Pieces. Inflamm Bowel Dis 2018;24:1352-60. [PMID: 29718228 DOI: 10.1093/ibd/izy013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
24 Miyazaki M, Nakashima A, Nakamura Y, Sakamoto Y, Matsuo K, Goto M, Uchiyama M, Okamura K, Mitsutake R, Urata H, Kamimura H, Imakyure O. Association between medication adherence and illness perceptions in atrial fibrillation patients treated with direct oral anticoagulants: An observational cross-sectional pilot study. PLoS One 2018;13:e0204814. [PMID: 30265710 DOI: 10.1371/journal.pone.0204814] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
25 Pouillon L, Socha M, Demore B, Thilly N, Abitbol V, Danese S, Peyrin-Biroulet L. The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol 2018;14:739-49. [PMID: 30118338 DOI: 10.1080/1744666X.2018.1512406] [Cited by in Crossref: 41] [Cited by in F6Publishing: 14] [Article Influence: 13.7] [Reference Citation Analysis]
26 Hong SW, Park J, Yoon H, Yang HR, Shin CM, Park YS, Kim N, Lee DH, Kim JS. Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease. Korean J Intern Med 2021;36:S9-S17. [PMID: 32580540 DOI: 10.3904/kjim.2019.279] [Reference Citation Analysis]
27 Polak EJ, O'Callaghan F, Oaten M. Perceptions of IBD within patient and community samples: a systematic review. Psychol Health 2020;35:425-48. [PMID: 31538517 DOI: 10.1080/08870446.2019.1662014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
28 Mittal M, Yang M, Shah M, Gao W, Carley C, Sherman BW. Impact of Medication Adherence on Healthcare Resource Utilization, Work Loss, and Associated Costs in a Privately Insured Employed Population Treated With Adalimumab in the United States. J Occup Environ Med 2021;63:e724-31. [PMID: 34412091 DOI: 10.1097/JOM.0000000000002354] [Reference Citation Analysis]
29 Park J, Yoon H, Shin CM, Park YS, Kim N, Lee DH. Higher levels of disease-related knowledge reduce medical acceleration in patients with inflammatory bowel disease. PLoS One. 2020;15:e0233654. [PMID: 32502199 DOI: 10.1371/journal.pone.0233654] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 290] [Article Influence: 180.5] [Reference Citation Analysis]
31 Haar GS, Vasudevan A, Curtain CM, van Langenberg DR. Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease. Res Social Adm Pharm 2021;17:1420-5. [PMID: 33129684 DOI: 10.1016/j.sapharm.2020.10.011] [Reference Citation Analysis]
32 Barnes A, Andrews J, Spizzo P, Mountifield R. Medication adherence and complementary therapy usage in inflammatory bowel disease patients during the coronavirus disease 2019 pandemic. JGH Open 2021;5:585-9. [PMID: 34013059 DOI: 10.1002/jgh3.12537] [Reference Citation Analysis]
33 Severs M, Mangen MJ, Fidder HH, van der Valk ME, van der Have M, van Bodegraven AA, Clemens CHM, Dijkstra G, Jansen JM, de Jong DJ, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Pierik M, Ponsioen CY, Romberg-Camps MJL, Siersema PD, Jharap B, van der Woude JC, Zuithoff NPA, Oldenburg B. Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1568-76. [PMID: 28700534 DOI: 10.1097/MIB.0000000000001201] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
34 Dolovich C, Bernstein CN, Singh H, Nugent Z, Tennakoon A, Shafer LA, Marrie RA, Sareen J, Targownik LE. Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2021;19:1200-1208.e1. [PMID: 32668341 DOI: 10.1016/j.cgh.2020.07.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Zhao S, Zhao H, Wang X, Gao C, Qin Y, Cai H, Chen B, Cao J. Factors influencing medication knowledge and beliefs on warfarin adherence among patients with atrial fibrillation in China. Patient Prefer Adherence 2017;11:213-20. [PMID: 28223782 DOI: 10.2147/PPA.S120962] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
36 Naviglio S, Giuffrida P, Stocco G, Lenti MV, Ventura A, Corazza GR, Di Sabatino A. How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2018;12:797-810. [DOI: 10.1080/17474124.2018.1494573] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]